Hearing Roth Capital Partners Raises Helius Medical Technologies PT To $24
Portfolio Pulse from Benzinga Newsdesk
Roth Capital Partners has increased the price target for Helius Medical Technologies (HSDT) to $24, indicating a positive outlook on the company's future performance.

March 05, 2024 | 5:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roth Capital Partners has raised the price target for Helius Medical Technologies to $24, suggesting a strong future performance.
The increase in price target by a reputable financial firm like Roth Capital Partners typically signals a bullish outlook on the stock, potentially leading to increased investor confidence and a rise in stock price in the short term.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100